P475 - LBA_ECE_1057 - Clinical outcome and safety profile of combination therapy with low-dose semaglutide and metformin vs metformin alone in polycystic ovary syndrome with obesity
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder where obesity exacerbates metabolic and androgenic features. The combination of low-dose semaglutide and metformin in South Asian women with PCOS and obesity may be an effective and safe treatment modality.
To compare the effectiveness and safety of a combined low-dose semaglutide and metformin with metformin alone in women with PCOS and obesity.
This Phase II randomized controlled trial was conducted at the Department of Endocrinology at Bangladesh Medical University from January 11 to October 16, 2025. A total of 31 reproductive-aged Bangladeshi women with PCOS and obesity (BMI ≥ 27.5 kg/m2) were randomly assigned to two groups. The metformin group (n = 16) received 1000 mg of metformin daily. The combination group (n = 15) received the same metformin dose plus subcutaneous semaglutide, starting at 0.25 mg weekly for 4 weeks, then increasing to 0.5 mg weekly for 12 weeks. Both groups received similar standardized lifestyle modifications. Clinical and metabolic data were collected at baseline and after 16 weeks, with interim evaluations at weeks 4, 8, and 12. Data analysis used paired and independent t-tests, Mann-Whitney U test, Chi-square test, and Fisher's Exact test, with a significance level set at P < .05.
The combination therapy group achieved greater reduction in body weight (mean difference, MD = −4.6%, P = .001), waist circumference (MD = −5.7%, P < .001), hip circumference (MD = −3.2%, P < .001),…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 16 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.